- Home
- MGNX vs GECC Comparison
MGNX vs GECC Comparison
Compare MGNX & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGNX | GECC |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 107.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGNX | GECC |
|---|---|---|
| Price | $1.40 | $7.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $3.20 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.4M | 91.2K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 19.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,626,000.00 | $46,553,000.00 |
| Revenue This Year | N/A | $32.16 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.68 |
| 52 Week Low | $0.99 | $7.18 |
| 52 Week High | $3.60 | $11.46 |
Technical Indicators
Market Signals| Indicator | MGNX | GECC |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 47.78 |
| Support Level | $1.32 | $7.57 |
| Resistance Level | $1.47 | $7.80 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 34.78 | 56.14 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.